# Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?

> **NCT01048268** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Gentofte, Copenhagen** · enrollment: 30 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** glucose-dependent insulinotropic polypeptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01048268
- **Lead sponsor:** University Hospital, Gentofte, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048268, "Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01048268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*